Global healthcare – Page 44 – Global Reach Health

September 20, 2021

Yusimry Approved as Humira Biosimilar

December 20, 2021 – Yusimry^TM (adalimumab-aqvh), manufactured by Coherus BioSciences, has been approved as a biosimilar for AbbVie's Humira^® (adalimumab)

September 16, 2021

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2021/09/lung-cancer-480x360.jpg" class="scale-with-grid wp-post-image" alt="lung-cancer" decoding="async" />

lung-cancer

New Lung Cancer Drug Exkivity Receives FDA Approval

September 16, 2021 – Takeda's Exkivity^TM (mobocertinib) has received U.S. FDA approval to treat adults who have locally advanced or metastatic

September 16, 2021

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2021/09/Pfizer-Expands-Chantix-Recall-480x360.jpg" class="scale-with-grid wp-post-image" alt="Pfizer-Expands-Chantix-Recall" decoding="async" />

Pfizer-Expands-Chantix-Recall

Pfizer Expands Chantix Recall to Include all 0.5mg and 1mg Tablets

September 16, 2021 – Pfizer is now recalling all lots of Chantix^® (varenicline) 0.5mg and 1mg tablets in the United States due to excess levels of a nitrosamine called

September 16, 2021

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2021/09/Lymphoma-Indications-480x360.jpg" class="scale-with-grid wp-post-image" alt="Lymphoma-Indications" decoding="async" />

Lymphoma-Indications

Brukinsa Receives Two New Lymphoma Indications

September 16, 2021 – The U.S. FDA has approved two new indications for Brukinsa^® (zanubrutinib), the first to treat adults who have Waldenström's macroglobulinemia

September 16, 2021

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2021/09/Two-Drug-Therapy-Authorized-for-COVID-19-Post-Exposure-Prevention-1-480x360.jpg" class="scale-with-grid wp-post-image" alt="Two-Drug-Therapy-Authorized-for-COVID-19-Post-Exposure-Prevention" decoding="async" />

Two-Drug-Therapy-Authorized-for-COVID-19-Post-Exposure-Prevention

Two-Drug Therapy Authorized for COVID-19 Post-Exposure Prevention

September 16, 2021 – The U.S. FDA has expanded the emergency use authorization (EUA) for Eli Lilly's investigation drugs bamlanivimab and etesevimab

September 13, 2021

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2021/09/Three-Lots-of-Ruzurgi-Recalled-Due-to-Contamination-480x360.jpg" class="scale-with-grid wp-post-image" alt="Three-Lots-of-Ruzurgi-Recalled-Due-to-Contamination" decoding="async" />

Three-Lots-of-Ruzurgi-Recalled-Due-to-Contamination

Three Lots of Ruzurgi Recalled Due to Contamination

September 13, 2021 – Jacobus Pharmaceutical Company recalled three lots of Ruzurgi^® (amifampridine) 10mg tablets. Laboratory test found

September 12, 2021

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2021/09/Cabometyx-Now-Indicated-to-Treat-Common-Form-of-Thyroid-Cancer-480x360.jpg" class="scale-with-grid wp-post-image" alt="Cabometyx-Now-Indicated-to-Treat-Common-Form-of-Thyroid-Cancer" decoding="async" />

Cabometyx-Now-Indicated-to-Treat-Common-Form-of-Thyroid-Cancer

Cabometyx Now Indicated to Treat Common Form of Thyroid Cancer

September 17, 2022 – Cabometyx^® (cabozantinib) is now U.S. FDA approved for to treat patients at least 12 years old who are radioactive iodine-refractory

September 8, 2021

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2021/09/One-Lot-of-Firvanq-Recalled-After-Being-Packaged-with-Wrong-Diluent-480x360.jpg" class="scale-with-grid wp-post-image" alt="One-Lot-of-Firvanq-Recalled-After-Being-Packaged-with-Wrong-Diluent" decoding="async" />

One-Lot-of-Firvanq-Recalled-After-Being-Packaged-with-Wrong-Diluent

One Lot of Firvanq Recalled After Being Packaged with Wrong Diluent

September 8, 2021 – Azurity Pharmaceuticals has recalled one lot of Firvanq^® (vancomycin hydrochloride for oral solution), Vancomycin 50mg/mL Kit